Use of a Multiplex Immunoassay Platform to Investigate Multifaceted Antibody Responses in SARS-CoV-2 Vaccinees with and Without Prior Infection

COVID, Год журнала: 2025, Номер 5(4), С. 44 - 44

Опубликована: Март 22, 2025

The emergence of COVID-19 necessitated the rapid development vaccines. While highly effective at reducing severe disease and death, breakthrough infections remain a problem as virus continues to mutate. To help address this issue, we show utility multiplex immunoassay in measuring multiple aspects antibody response generated by SARS-CoV-2 We use platform measure spike-specific IgG concentration, avidity, receptor-binding inhibition. In addition, correlate results from an ACE-2 inhibition assay with corresponding data microneutralization establish inhibitory potential predictor neutralization. studied these responses SARS-CoV-2-naïve -convalescent vaccinees. Our showed increased concentrations, following vaccination both groups. were also able differentiate immune between two groups using look diversity. has strong correlations cell-based pseudovirus neutralization well WT Washington Delta variant PRNT50 assays. This suggests that may be simultaneously predict different variants. Overall, developed custom several experimental variations is powerful tool assessing vaccinated individuals.

Язык: Английский

---

A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland

BMC Infectious Diseases, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 7, 2025

Abstract Background New vaccines with broader protection against SARS-CoV-2 are needed to reduce the risk of immune escape and provide broad long-lasting cellular immunity. The objectives naNO-COVID trial were evaluate safety immunogenicity a CD8 + T cell, gold nanoparticle-based, peptide COVID-19 vaccine. Methods A randomized, double-blind, vehicle-controlled, phase 1 in healthy adults receive PepGNP-Covid19 or Vehicle-GNP, followed over 180 days, using dose-escalation strategy. Results Twenty participants received (low dose [LD] high [HD], n = 10 each) six Vehicle-GNP (LD HD, 3 each). Vaccinations safe. No serious adverse events reported. Most mild, two special interest related product (fever fatigue). Reactogenicity was similar overall between vaccine, comparator, doses. Virus-specific humoral responses LD groups coincided infections. vaccination induced modulation Covid19-specific CD137 CD69 , an increase at day 35 particularly central effector memory cells group, late HD group. Conclusions favourable profile observed support further development PepGNP-Covid19. Trial registration ClinicalTrials.gov, NCT05113862, approved 09.11.2021.

Язык: Английский

---

SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination

Vaccines, Год журнала: 2023, Номер 11(7), С. 1186 - 1186

Опубликована: Июнь 30, 2023

(1) Background: SARS-CoV-2 T cell immunity is rapidly activated following infection and vaccination crucial for controlling progression severity. The aim of the present study was to compare levels responses between cohorts subjects with hybrid (convalescent vaccinated), vaccinated naïve (non-exposed) convalescent unvaccinated subjects. (2) Methods: We performed a retrospective descriptive analysis data collected from medical records adult individuals who were consecutively examined at large, private Medical Center Attica September 2021 2022 in order be on their own initiative response. They divided into three groups: Group A: subjects; B: C: response estimated against spike (S) nucleocapsid (N) structural proteins by performing methodology T-SPOT.COVID test. (3) Results: A total 530 retrospectively included study, 252 females (47.5%) 278 (52.5%) males ranging 13 92 years old (mean 55.68 ± 17.0 years). Among them, 66 (12.5%) A, 284 (53.6%) B 180 (34.0%) C. groups, reaction S antigen reported 58/66 (87.8%) 175/284 (61.6%) 146/180 (81.1%) C (chi-square, p < 0.001). Reaction N 49/66 (74.2%) 140/180 (77.7%) = 0.841). median SFC count 24 (range 0-218) 12 0-275) 18 0-160) (Kruskal-Wallis test, 0.001; pairwise comparisons: groups A-B, A-C, 0.147; B-C, SFCs 0-82) 0-168) 0.27 A-C groups). (4) Conclusions: Our findings suggest that natural cellular immunity, either alone or combined vaccination, confers stronger more durable protection compared vaccine-induced immunity.

Язык: Английский

---

A prognostic model for SARS-CoV-2 breakthrough infection: Analyzing a prospective cellular immunity cohort

International Immunopharmacology, Год журнала: 2024, Номер 131, С. 111829 - 111829

Опубликована: Март 14, 2024

Язык: Английский

---

Enhancement of subunit vaccine delivery with zinc-carnosine coordination polymer through the addition of mannan

International Journal of Pharmaceutics, Год журнала: 2024, Номер 656, С. 124076 - 124076

Опубликована: Апрель 1, 2024

Язык: Английский

---